logo

Ocular Therapeutix Inc. (OCUL)



Trade OCUL now with
  Date
  Headline
7/19/2018 8:08:28 AM Ocular Therapeutix Announces FDA Acceptance Of NDA Resubmission For DEXTENZA
6/29/2018 8:03:56 AM Ocular Therapeutix Announces NDA Resubmission Of DEXTENZA
5/3/2018 8:43:06 AM Ocular Announces Treatment Of 1st Patient In Phase 1 Trial Of OTX-TIC For Treatment Of Glaucoma And Ocular Hypertension
3/8/2018 7:33:10 AM Ocular Therapeutix Q4 Loss/shr $0.44 Vs. Loss/shr $0.52 Prior Year
1/25/2018 9:11:01 AM Ocular Therapeutix Prices Underwritten Public Offering Of 6.50 Mln Shares At $5.00/shr For Gross Proceeds Of $32.5 Mln
1/24/2018 4:02:28 PM Ocular Therapeutix Announces Proposed Public Offering Of Common Stock
9/25/2017 8:05:19 AM Ocular Therapeutix Appoints Donald Notman As CFO
9/8/2017 9:03:06 AM Ocular Therapeutix Appoints Michael Goldstein As Chief Medical Officer
8/1/2017 4:28:58 PM Ocular To Eliminate 26 Positions, Representing 19% Of Its Workforce